Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
S
P 271
SAFETY AND EFFICACY OF CABOZANTINIB IN PEDIATRIC PATIENTS WITH MALIGNANT SOLID TUMORS (CAMEL TRIAL/NCCH2106): A SINGLE-CENTRE PHASE I TRIAL
Favorite
P 436
SAKK 57/24 FEASIBILITY OF TOTAL NEOADJUVANT TREATMENT WITH HYPERTHERMIA IN PATIENTS WITH HIGH-RISK EXTREMITY AND TRUNK SOFT TISSUE SARCOMA. A MULTICENTER, SINGLE ARM, OPEN LABEL, PHASE II TRIAL
Favorite
P 345
SARCOMA BIOPSY COMPARISON BETWEEN REFERRAL CENTERS AND TREATING CENTERS: THE MUSCULOSKELETAL TUMOR REGISTRY (MSTR) EXPERIENCE
Favorite
P 209
SARCOMA PATIENT COMMUNITY DATA COLLABORATION TO ADVANCE RESEARCH
Favorite
P 19
SERUM EXOSOMES IDENTIFY AN ABERRANT PROTEOMIC SIGNATURE IN CANINE OSTEOSARCOMA PRECEDING METASTATIC PROGRESSION
Favorite
P 215
SHAPEHUB: A MULTICENTRE REAL-WORLD-TIME DATA PLATFORM WITH DIGITAL TWIN ENGINE FOR A LEARNING HEALTH SYSTEM IN SARCOMA
Favorite
P 362
SHOULD PAZOPANIB BE USED AS A MAINTENANCE THERAPY TO IMPROVE RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WHO RECEIVED MAI IN SOFT TISSUE SARCOMA?
Favorite
P 151
SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Favorite
P 313
SIGNIFICANCE OF LYMPH NODE PROCEDURES IN SOFT TISSUE SARCOMA PATIENTS
Favorite
P 22
SINGLE CELL SEQUENCING ENABLES LINEAGE-INFORMED TARGETING OF OSTEOSARCOMA
Favorite
P 429
SINGLE-ARM, OPEN-LABEL PHASE II TRIAL OF XL092 (ZANZALINTINIB) IN PATIENTS WITH ADVANCED LEIOMYOSARCOMA: TRIAL IN PROGRESS
Favorite
P 126
SINGLE-CELL RNA SEQUENCING AND PROTEOMIC SPATIAL PROFILING REVEAL COMPLEX TUMOR MICROENVIRONMENT AND NOVEL IMMUNE INTERACTIONS IN CHONDROSARCOMA
Favorite
P 247
SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Favorite
P 115
SINGLE-CENTER EXPERIENCE WITH TYROSIN KINASA INHIBITORS IN ADVANCED BONE SARCOMA: EFFICACY AND SAFETY OUTCOMES
Favorite
P 289
SIX YEAR FOLLOW-UP ON CIVASHEET® USE FOR SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 251
SPATIAL MULTI-OMIC ANALYSIS OF RHABDOMYOSARCOMA IDENTIFIES THERAPEUTIC VULNERABILITIES
Favorite
P 307
STRATEGIES FOR DATA QUALITY IN TARPSWG RETROPERITONEAL SARCOMA REGISTRY (RESAR)
Favorite
P 57
STUDYING HYPOXIA-INDUCED METASTASIS IN GENETICALLY ENGINEERED MOUSE MODELS OF UPS
Favorite
P 410
SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Favorite
P 245
SUBTYPE SPECIFIC CHARACTERIZATION OF IMMUNE INFILTRATION IN SOFT TISSE SARCOMAS
Favorite
P 149
SURGICAL TEXTBOOK OUTCOMES IN PATIENTS DIAGNOSED WITH CHONDROSARCOMA
Favorite
P 346
SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Favorite
P 196
SURVEILLANCE STRATEGIES AND LONG-TERM OUTCOMES IN LOW-RISK GASTRIC GASTROINTESTINAL STROMAL TUMORS (GGISTS)
Favorite
P 347
SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS OF SOFT TISSUE SARCOMAS OF THE TRUNK AND EXTREMITIES TREATED BETWEEN 2010 AND 2015: EXPERIENCE OF THE BRAZILIAN NATIONAL CANCER INSTITUTE
Favorite
P 120
SURVIVAL OUTCOMES AND ROLE OF CHEMOTHERAPY IN PATIENTS OLDER THAN 40 YEARS WITH OSTEOSARCOMA (OLD-SARC STUDY).
Favorite
P 261
SUSTAINED RESPONSE WITH RIVOCERANIB AND DENOSUMAB IN RELASPED OSTEOSARCOMA
Favorite
P 348
SYNOVIAL SARCOMA INVOLVING NERVES: HIGH RATE OF MISIDENTIFICATION AS BENIGN TUMORS
Favorite
